Due to the limited number of completed clinical and preclinical studies aimed at elucidating the mechanism(s) and extent by which GLP-1R agonists influence diastolic dysfunction in T2DM, further work is clearly necessary to understand the clinical role GLP-1R agonists will play in managing diabetic cardiomyopathy. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.